Boehringer Ingelheim, a Germany-based biopharmaceutical company, announced on Friday that it has received a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS (zongertinib tablets).
HERNEXEOS is currently under investigation for first-line use in treatment-naive patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
The CNPV program looks to reduce the review process from a typical tome-scale of 10-12 months to one to two months, while maintaining the FDA's rigorous safety and efficacy standards.
This honour is claimed to reflect the potential of HERNEXEOS to meet critical patient requirements for this rare and aggressive cancer.
The FDA chose HERNEXEOS for the CNPV program.
Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection
Luminopia agrees international licensing deal for paediatric amblyopia treatment in Japan
FDA accepts Genentech's giredestrant application for early-stage breast cancer
Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC
Hanmi signs licensing deal with Lilly for sonefpeglutide
FDA approves TREMFYA label expansion
GSK reports positive phase III data for bepirovirsen in chronic hepatitis B
Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease
CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network
Ribo submits Phase 2 trial application for RBD1119 to European regulator
US FDA extends review timeline for AstraZeneca's camizestrant application
Orsini to chosen as contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod)
Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China
Lundbeck's Vyepti (eptinezumab) receives South Korean approval for preventive treatment of migraine